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Introduction {#sec005}
============

Approximately 1,638,910 new cancer diagnoses and about 577,190 deaths occurred in the US in 2012, mostly from solid tumors \[[@pone.0143080.ref001]\]. Prognostication in cancer can be either subjective or objective. In the former, dependent on clinician skill and experience, it is often inaccurate and usually overly optimistic \[[@pone.0143080.ref002]\]. Prognostication is an important clinical skill for oncologists. Despite advances in medical technology and biology, it is still an inexact science \[[@pone.0143080.ref002]\], even with extensive and expensive investigations \[[@pone.0143080.ref003]\]. Objective determination of prognosis can be based on a combination of tumor, patient, and environmental factors. The use of biological tumor markers to help prognostication (alone or combined with other parameters) has appeal. An ideal potential tumor marker should have a long half-life, be measured accurately and precisely by a simple and inexpensive blood test. It is also important that it be sensitive to change so that it can be followed over time through serial measurements. A few biologic markers meet these criteria \[[@pone.0143080.ref004]\]. C-reactive protein (CRP) is one.

Rationale {#sec006}
---------

CRP is an acute phase reactant, which reflects tissue injury \[[@pone.0143080.ref005]\]. The half-life is 19 hours in both health and disease. CRP secretion by hepatocytes appears controlled by interleukin 6 (IL-6). Interleukin-1 (IL-1) and tumor necrosis factor (TNF) also stimulate CRP synthesis \[[@pone.0143080.ref006]\]. CRP is a stable downstream marker of inflammation, unlike the pro-inflammatory cytokines, which have short half-lives (minutes) \[[@pone.0143080.ref007], [@pone.0143080.ref008]\]. In chronic inflammatory diseases, serial CRP levels have been correlated with disease severity, and response to therapy \[[@pone.0143080.ref009]\]. Many large prospective studies now support the role of CRP in prediction of coronary artery disease \[[@pone.0143080.ref010], [@pone.0143080.ref011]\], though controversies exist \[[@pone.0143080.ref012]\].

Chronic inflammation has been linked to cancer at tumor initiation, but may also be associated with invasive potential and disease progression \[[@pone.0143080.ref013], [@pone.0143080.ref014]\]. A relationship has been proposed between systemic inflammation and various cancer symptoms \[[@pone.0143080.ref015]\]. A strong positive correlation between high CRP and high IL-6 levels was shown in advanced pancreatic cancer \[[@pone.0143080.ref016]\]. Elevated CRP levels have been linked to shorter survival in several common cancers \[[@pone.0143080.ref017]\].

Objectives {#sec007}
----------

In this paper, we describe the results of a systematic review of the relationship between elevated serum CRP and life expectancy in people with solid tumors. We also examined its role in the prediction of treatment response and risk of tumor recurrence.

Methods {#sec008}
=======

Eligibility criteria {#sec009}
--------------------

Only articles in English were included. Original reports of any studies of solid malignancies in adults were scrutinized. All study designs were included. The following articles were excluded: all non-English literature, basic research, animal research, all pediatric and hematological malignancies, and studies where prognostic parameters were not assessed, or serum CRP levels not measured. Editorial letters and comments were also excluded. Review papers were consulted, but for discussion purposes only.

Information sources {#sec010}
-------------------

Electronic databases included: PubMed (1966 to December 2012); EMBASE (1988 to 2012); Web of Science (1980 to 2012); SCOPUS (1965 to 2012); and the EBM-Cochrane Central Register of Controlled trials and EBM-Cochrane Database of Systematic Reviews (Up to 2012). The search was repeated at the end of data analysis.

Search {#sec011}
------

PubMed search of CRP or related MeSH terms (c---reactive protein/c-reactive) with (AND) neoplasm/neoplasms/cancer in all fields with (AND) prognosis/mortality/survival OR survival rate/treatment outcome/treatment/outcome was done including other databases. Search words/terms were as follows:

Study selection {#sec012}
---------------

A qualified medical librarian (see Acknowledgements) reviewed the search strategy. The first literature screen ([Fig 1](#pone.0143080.g001){ref-type="fig"}) was based on article title. If that was irrelevant, the abstract was also reviewed (by NBB, SS and DW) before an exclusion decision. Abstracts (and when necessary the full text) of the remaining articles were then assessed. The reviewers (NBB, SS, ST and DW) met periodically to discuss reasons of exclusion or inclusion of selected papers. Retained articles were then subjected to quality assessment ([S1 Appendix](#pone.0143080.s001){ref-type="supplementary-material"}).

![Studies Selection.](pone.0143080.g001){#pone.0143080.g001}

Quality assessment {#sec013}
------------------

A quality assessment (QA) system was developed. This was based on existing guidelines \[[@pone.0143080.ref018], [@pone.0143080.ref019]\] for observational cohort prognostic studies. The tool combined five criteria:

1.  Study design

2.  Patient selection

3.  Prognostic variables

4.  Follow-up

5.  Data analysis

A score of 0--2 was assigned to each---if a study met the conditions in full (score of 2), partially (score of 1), or not at all (score of 0) ([S1 Appendix](#pone.0143080.s001){ref-type="supplementary-material"}). The total was expressed as a percentage of the maximum possible score. A score of 80--100% was ranked as an adequate study; ≥50 but \<80% as intermediate; articles that scored \<50% were considered inadequate and excluded from the review ([S2 Appendix](#pone.0143080.s002){ref-type="supplementary-material"}).

Data collection {#sec014}
---------------

Data were extracted using a custom designed extraction sheet (till 2010) and later utilizing the Research Electronic Data Capture (REDCap) \[[@pone.0143080.ref020]\] forms with same sheet. REDCap is a secure web application to create and manage data. The following information was collected: author name, publication date, study title, study design, quality assessment score and grade, number of patients and controls (when available), cancer type, extent of disease, main outcome, main results related to prognosis or treatment outcomes, CRP cut-off points, assay method, mean CRP value, survival definition, median survival duration, CRP sensitivity and specificity as a predictor of prognosis, treatment outcomes or recurrence, other parameters assessed for prognosis, strongest predictors of prognosis, statistical analysis used, and possible co-morbid contributors to increased CRP levels other than cancer (like infection, chemo- or radiotherapy, surgery). The descriptor term "cutoff" refers to the value an investigator/author used to determine an "elevated" CRP even if that level was within the biochemical reference range.

Summary measures {#sec015}
----------------

There was substantial variation in study design and cancer primary sites. A meta-analysis was therefore inappropriate. For each study article we estimated the minimum sample size necessary to detect a difference at P ≤ 0.05. We used the general rule of n = 10 per variable. The estimated minimum sample size was compared to the actual size of the study. Studies with insufficient sample sizes were considered underpowered. Predictors by multivariate analysis were stratified by relative risk (RR) and statistical significance (p-value):

1.  When RR\<2 or \>0.5

2.  When RR\>2 or \<0.5

3.  When RR\>5 or \<0.2

4.  When RR\>10 or \<0.1

5.  When p\<0.05

6.  When p\<0.01

7.  When p\<0.001

We followed the PRISMA statement ([S1 PRISMA Checklist](#pone.0143080.s007){ref-type="supplementary-material"}) to design and report our systematic review \[[@pone.0143080.ref021]\].

Results {#sec016}
=======

Study selection {#sec017}
---------------

The search identified three thousand and eighty nine (3089) citations: fourteen hundred sixty-six (1466) in PubMed, eight hundred two (802) in Web of Science, three hundred twenty (320) in SCOPUS, three hundred eleven (311) in EMBASE and one hundred ninety (190) in the Cochrane database. After removal of duplicates, fifteen hundred twenty six (1526) remained. Irrelevant studies were then removed. These included those where survival or prognosis was not an outcome, studies where CRP was not studied as a prognostic marker, animal/cell-line based studies, letters and editorials, and those that did not fit our inclusion criteria. Seven hundred thirty one (731) papers were left. Next, three hundred (300) studies in hematologic malignancies, ten (10) non-English articles and forty two (42) pediatric reports were removed. Subsequent to the quality assessment (QA) of the three hundred seventy nine (379) studies retained, thirty five (ten prospective, twenty five retrospective) were inadequate by QA score and excluded. Then two hundred seventy one (271) research studies and seventy-three (73) review papers remained ([Fig 1](#pone.0143080.g001){ref-type="fig"}). Survival and outcome measures differed between studies. As a result, no direct study comparisons were possible.

Two hundred seventy one original articles constituted the final analysis ([Fig 1](#pone.0143080.g001){ref-type="fig"}). Only seven of these scored ≥ 80% in the QA (all were prospective and longitudinal, and with a control group in three). Two hundred sixty four (264) had an intermediate QA score. One hundred twenty nine (129) of the 271 did not describe their patient selection procedures. Examples included whether patients were screened for infections, the timing of CRP measurement in relation to factors that could raise CRP level (like chemo- or radiation therapy), and invasive procedures. The sensitivity and specificity of the predictive prognostic value of CRP were reported in only four studies \[[@pone.0143080.ref022]--[@pone.0143080.ref025]\], two in melanoma, one each in cancer of the esophagus and lung. A power analysis was described in two \[[@pone.0143080.ref026], [@pone.0143080.ref027]\]; CRP was an independent prognostic marker of survival in one but not the other. The reference level of CRP for evaluation of responses varied both for RCC and GI studies.

Study characteristics by study design {#sec018}
-------------------------------------

Forty five percent (n = 122) of the studies were prospective and 52% (N = 142) of the 271 studies were retrospective; the remaining 3% (N = 7) combined retrospective and prospective design. In the prospective studies, median sample size was 121 (range 15--9605) versus 146 (range 32--9608) in the retrospective. High CRP predicted prognosis in 82% (100/122) of the prospective studies. In 13% (16/122) of prospective studies, this was by univariate analysis only. In 18% (22/122), CRP was not prognostic of survival ([Table 1](#pone.0143080.t001){ref-type="table"}). Only 16% (20 of 122) of the prospective studies had a control group (CG) ([Table 1](#pone.0143080.t001){ref-type="table"}). Overall CRP predicted prognosis in 90% (245/271) of studies; 80% by multivariate analysis (MVA) and 20% by univariate analysis (UVA) ([Table 2](#pone.0143080.t002){ref-type="table"}).

10.1371/journal.pone.0143080.t001

###### Characteristics by Study Design.

![](pone.0143080.t001){#pone.0143080.t001g}

  Study Type                                            Number of Studies   Sample Size   Study Outcomes[^\#^](#t001fn005){ref-type="table-fn"} (%)                        
  ----------------------------------------------------- ------------------- ------------- ----------------------------------------------------------- ---------- --------- ---------
  **Prospective**                                       122 (45)            121           (15--9605)                                                  100 (82)   22 (18)   16 (13)
  No control group                                      102 (84)            117           (15--9605)                                                                       
  Control group                                         20 (16)             156           (54--687)                                                                        
  **Retrospective**                                     142 (52)            146           (32--9608)                                                  128 (90)   14 (10)   29 (20)
  **Combined** [^+^](#t001fn006){ref-type="table-fn"}   7 (3)               98            (58--325)                                                   7 (100)    0         0

**1**: Number of Studies Where CRP was a Prognostic Predictor.

**2**: Number of Studies Where CRP was Not a Prognostic Predictor.

**3**: Number of Studies Where CRP was a Prognostic Predictor by Univariate Analysis Only.

\* Percent (rounded to the closest whole number) compared to total number of studies.

^**\#**^ Percent compared to study type.

^**+**^ Both prospective and retrospective data.

10.1371/journal.pone.0143080.t002

###### Study Characteristics by Tumor Type.

![](pone.0143080.t002){#pone.0143080.t002g}

  Cancer Type                                             Number of Studies   Study Outcomes            
  ------------------------------------------------------- ------------------- ---------------- -------- ---------
  Digestive Tumors[\*](#t002fn004){ref-type="table-fn"}   90                  81 (90)          9 (10)   16 (18)
  Renal cell carcinoma                                    51                  46 (90)          5 (10)   12 (24)
  Pancreas                                                24                  23 (96)          1 (4)    7 (29)
  Lung                                                    24                  22 (92)          2 (8)    2 (8)
  Hepatocellular carcinoma (HCC)                          10                  10 (100)         0 (0)    1 (10)
  Melanoma                                                5                   5 (100)          0 (0)    0 (0)
  Breast                                                  7                   4 (57)           3 (43)   0 (0)
  Prostate                                                9                   7 (78)           2 (22)   0 (0)
  Bladder                                                 12                  12 (100)         0 (0)    2 (17)
  Heterogeneous                                           15                  14 (93)          1 (7)    2 (13)
  Others                                                  24                  21 (88)          3 (13)   6 (25)

**1**: Number of Studies Where CRP was a Prognostic Predictor.

**2**: Number of Studies Where CRP was Not a Prognostic Predictor.

**3**: Number of Studies Where CRP was a Prognostic Predictor on Univariate Analysis Only.

\* Digestive tumors include esophageal, gastroesophageal and intestinal tumors.

Study characteristics by tumor type {#sec019}
-----------------------------------

### 1. Renal cell carcinoma {#sec020}

Fifty one (19%) studies looked at renal cell carcinoma. Of these, CRP was prognostic in 90% (46 of 51). In 12 of 51 (24%), CRP predicted prognosis on univariate analysis only \[[@pone.0143080.ref028]--[@pone.0143080.ref037]\]. CRP was not predictive of prognosis in five studies \[[@pone.0143080.ref038]\] ([Table 2](#pone.0143080.t002){ref-type="table"}, [Fig 2](#pone.0143080.g002){ref-type="fig"}).

![CRP Prediction of Prognosis by Tumor Primary Site.](pone.0143080.g002){#pone.0143080.g002}

1.1 Prognosis: Forty-six of the 51 studies in renal cell carcinoma (90%) had prognosis as a primary outcome. In thirty three of the 46, CRP was a strong predictor of survival by multivariate analysis ([Table 3](#pone.0143080.t003){ref-type="table"}). In the other 12 of the 46, CRP predicted prognosis by univariate analysis only \[[@pone.0143080.ref028]--[@pone.0143080.ref037]\]. One of these was underpowered \[[@pone.0143080.ref039]\]; none of the other eleven studied the prognostic value of CRP as a primary outcome measure ([Table 3](#pone.0143080.t003){ref-type="table"}).

10.1371/journal.pone.0143080.t003

###### CRP as a Predictor of Prognosis, Treatment Outcome or Tumor Recurrence in Renal Cell Carcinoma.

![](pone.0143080.t003){#pone.0143080.t003g}

  Publication Year (Reference)                  Main Outcome                                                                               CRP cut-offs[\*](#t003fn001){ref-type="table-fn"} (mg/L)[^\#^](#t003fn002){ref-type="table-fn"}   Study Design                  Quality Score (%)   Sample Size                       Disease Extent      Strongest Predictors by MVA[^ϕ^](#t003fn003){ref-type="table-fn"}   
  --------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------- ----------------------------- ------------------- --------------------------------- ------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  **PROGNOSIS**                                                                                                                                                                                                                                                                                                                                                                                                          
  **1998** \[[@pone.0143080.ref144]\]           5 year Survival Post Curative Resection                                                    Negative vs. positive                                                                             Retrospective                 55                  111                               All stages          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     T stage                                                             [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **1999** \[[@pone.0143080.ref145]\]           Pre-treatment Serum Markers and Clinical Parameters                                        ≥8                                                                                                Prospective                   65                  99                                Metastatic          SICAM-1                                                             ---, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 ---, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     ESR                                                                 ---, [x](#t003fn008){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref146]\]           APP in Potentially Curative Resection                                                      \>10                                                                                              Prospective + Retrospective   60                  43 Prospective 57 Retrospective   All stages          CRP                                                                 [c](#t003fn006){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Grade                                                               [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Sex                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref147]\]           Estimation by Fractional Polynomials                                                       Not reported                                                                                      Retrospective                 65                  425                               Metastatic          Age                                                                 [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     LN, liver, bone metastasis                                          ---, [y](#t003fn009){ref-type="table-fn"},[x](#t003fn008){ref-type="table-fn"},[y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 ---, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Neutrophils                                                         ---, [y](#t003fn009){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref148]\]           Preoperative Serum CRP                                                                     \>5                                                                                               Prospective                   65                  101                               Localized           DSS: pT staging                                                     [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     RFS: CRP                                                            [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     pT Staging                                                          [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref149]\]           GPS and Cancer-specific Survival                                                           \>10                                                                                              Prospective                   70                  119                               Metastatic          Biochemical: Calcium                                                [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Albumin                                                             [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     WCC                                                                 [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Scoring systems: GPS                                                [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     MSKCC                                                               [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref150]\]           Stages Treated with Nephrectomy--Survival UISS v. Model with CRP                           Continuous Categorical: ≤4.0, 4.1--23.0, \>23.0                                                   Prospective                   65                  313                               All Stages          CRP (Cat.)                                                          ---, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Metastasis                                                          [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     ECOG PS                                                             [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref151]\]           Survival, Treatment Response: IL-2 Based Therapy                                           8mg/L                                                                                             Retrospective With Control    60                  55 + 144 Controls                 Metastatic          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     IL-12                                                               [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref050]\]           Survival: Primary Operable Tumor Recurrence                                                \>10mg/L                                                                                          Prospective                   75                  83                                All Stages          CRP                                                                 [d](#t003fn007){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     T-stage                                                             [d](#t003fn007){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Necrosis                                                            [d](#t003fn007){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref033]\]           Prognosis: RCC Extending IVC                                                               6mg/L                                                                                             Retrospective                 55                  46                                All Stages          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, ---
                                                                                                                                                                                                                                                                                                                                                     LN Metastasis                                                       [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref051]\]           CRP, Tumoral IL-6, COX-2 Expression & Survival                                             10mg/L                                                                                            Retrospective                 60                  60                                Resectable          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     TNM                                                                 [c](#t003fn006){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref152]\]           Systemic Symptoms on Survival                                                              3mg/L                                                                                             Retrospective                 55                  252                               All Stages          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Systemic Symptoms                                                   [c](#t003fn006){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref123]\]           Survival in Cytoreductive Nephrectomy                                                      5mg/L                                                                                             Prospective                   65                  40                                Metastatic          CRP kinetics                                                        [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Poor ECOG                                                           ---, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Number of Mastectomy                                                ---, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Bone Metastasis                                                     ---, [x](#t003fn008){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref122]\]           CRP Kinetics & Survival                                                                    Normalized & Non-Normalized                                                                       Retrospective                 60                  108                               Metastatic          Normal CRP                                                          [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Non-Normal CRP                                                      [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     ECOG PS                                                             [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     LDH                                                                 [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref153]\]           Survival Prediction Model with CRP                                                         5mg/L                                                                                             Prospective with Control      75                  249 Control-290                   Locally Advanced    CRP                                                                 [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Distant Metastasis                                                  [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref032]\]           Worst Grade Component Survival, Recurrence                                                 ≥10 mg/L                                                                                          Retrospective                 50                  314                               All Stages          CRP                                                                 [a](#t003fn004){ref-type="table-fn"},---
                                                                                                                                                                                                                                                                                                                                                     Distant Metastasis                                                  [c](#t003fn006){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref053]\]           Preoperative CRP Survival, Metastasis                                                      Continuous                                                                                        Prospective                   85                  130                               All Stages          Pre-operative CRP                                                   [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Pre-operative Platelets                                             [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref049]\]           Preoperative and Postoperative CRP to Predict Outcome                                      Continuous                                                                                        Prospective                   70                  110                               Localized           Post-operative CRP                                                  [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     T-stage                                                             [d](#t003fn007){ref-type="table-fn"}, ---
  **2010** \[[@pone.0143080.ref048]\]           Pre-operative Prognostic Significance of CRP                                               15mg/L                                                                                            Retrospective                 60                  286                               All Stages          Log (CRP)                                                           [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     M-Stage                                                             [b](#t003fn005){ref-type="table-fn"}, z
                                                                                                                                                                                                                                                                                                                                                     Necrosis                                                            [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     MVI (invasion)                                                      [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     RBC                                                                 [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     WBC                                                                 [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref037]\]           Lifestyle Factors on CRP and Overall Survival                                              2mg/L                                                                                             Prospective                   70                  257                               Localized           Pre-operative CRP                                                   [a](#t003fn004){ref-type="table-fn"}, ---
  **2011** \[[@pone.0143080.ref054]\]           CRP and Thrombocytosis on Survival                                                         8mg/L                                                                                             Retrospective                 55                  177                               Resectable          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Tumor size                                                          [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref154]\]           CRP on Survival, Predictive Survival Model                                                 3mg/L                                                                                             Retrospective                 50                  94                                Metastasis (Bone)   CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Sarcoma Differentiate                                               [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Bone Involvement                                                    [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Extraosseus Metastasis                                              [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     ALP                                                                 [c](#t003fn006){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref055]\]           CRP, CRP Kinetics: Survival and Recurrence                                                 10mg/L                                                                                            Retrospective                 55                  263                               Resectable          Non-normal CRP                                                      ---, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Anemia                                                              ---,---
                                                                                                                                                                                                                                                                                                                                                     Thrombocytosis                                                      ---,-
  **2011** \[[@pone.0143080.ref155]\]           Prognosis of Metastatic RCC; Validity of MSKCC                                             3mg/L                                                                                             Retrospective                 50                  473                               Metastasis          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Diagnosis→Metastasis (Time)                                         [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Hemoglobin                                                          [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Calcium                                                             [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     LDH                                                                 [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Liver metastasis                                                    [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Bone metastasis                                                     [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Node metastasis                                                     [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref056]\]           Factors Associated WithSurvival, Recurrence                                                4 mg/L                                                                                            Retrospective                 50                  32                                Metastasis          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref156]\]           Post-operative CRP, pre-operative albumin and survival                                     2 mg/L                                                                                            Retrospective                 50                  40                                Resectable          Postoperative CRP                                                   [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Preoperative Albumin                                                [c](#t003fn006){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref157]\]           mGPS and Prognosis                                                                         10 mg/L (mGPS)                                                                                    Prospective                   70                  169                               All Stages          mGPS                                                                [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Necrosis                                                            [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref158]\]           Systemic inflammation, Tumor inflammatory cells, Tumor Necrosis & Survival                 10mg/ L (mGPS)                                                                                    Prospective                   60                  79                                Resectable          mGPS                                                                [c](#t003fn006){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref159]\]           Survival & Treatment Response with Sunitinib                                               3mg/L                                                                                             Retrospective                 50                  41                                All Stages          Elevated CRP                                                        ---/---
                                                                                                                                                                                                                                                                                                                                                     Normal CRP                                                          [d](#t003fn007){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref160]\]           Molecular-targeted agents, Survival & Treatment Response                                   8mg/L                                                                                             Retrospective                 55                  52                                Metastasis          CRP                                                                 [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Neutrophilia                                                        [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref161]\]           Hyponatremia on Survival with Molecular Targeted Therapy                                   10mg/L                                                                                            Retrospective                 50                  87                                Metastasis          Severe Hyponatremia                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Mild Hyponatremia                                                   [c](#t003fn006){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Neutrophilia                                                        [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref162]\]           WBC, CRP and Survival, Optimal Threshold of CRP                                            25mg/L                                                                                            Retrospective                 55                  327                               Resectable          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     T stage                                                             [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     N stage                                                             [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     M stage                                                             [c](#t003fn006){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Nuclear grade                                                       [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Karnofsky                                                           [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref163]\]           Prognostic significance of Osteopontin A, Carbonic Anhydrase IX, CRP; alone and combined   Continuous                                                                                        Retrospective                 55                  216                               All Stages          CRP                                                                 [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CA-9                                                                [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     N stage                                                             [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     M stage                                                             [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref164]\]           Pre-operative CRP                                                                          Continuous Categorical: \<4mg/L, 4-10mg/L, \>10mg/L                                               Retrospective                 55                  1161                              All Stages          Metastasis                                                          [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     G4 Differentiation                                                  [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP (Continuous)                                                    [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP (Categorical)                                                   [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP (Categorical)                                                   [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **TREATMENT RESPONSE AND TUMOR RECURRENCE**                                                                                                                                                                                                                                                                                                                                                                            
  **1992** \[[@pone.0143080.ref040]\]           CRP and IL-2 Response                                                                      \>10                                                                                              Prospective                   60                  15                                Metastatic          CRP                                                                 ---
  **1992** \[[@pone.0143080.ref041]\]           Serum IL-6, pre-IL-2                                                                       \>50                                                                                              Prospective                   50                  138+ 70 controls                  Metastatic          CRP                                                                 ---
                                                                                                                                                                                                                                                                                                                                                     IL-6                                                                ---
  **1999** \[[@pone.0143080.ref042]\]           Cytoreductive Surgery Subgroups                                                            ≥1ng/ml                                                                                           Retrospective                 50                  58                                Metastatic          CRP                                                                 ---
  **2003** \[[@pone.0143080.ref043]\]           Prognostic System Post-IL-2 + INF-α                                                        ≥11                                                                                               Retrospective                 55                  425                               Metastatic          WBC                                                                 [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     LDH                                                                 [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Number of Metastasis                                                [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Time to Metastasis                                                  [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2004** \[[@pone.0143080.ref044]\]           APP, Performance Status and Survival post-IFN-α                                            ≤10 vs. \>10                                                                                      Prospective+ Retrospective    55                  26 Retrospective 32 Prospective   Advanced            CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2005** \[[@pone.0143080.ref045]\]           Pre-treatment (IL-2) Biohumoral and Clinical Factors                                       ≥8                                                                                                Retrospective                 60                  110                               Metastatic          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     DFI                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2005** \[[@pone.0143080.ref046]\]           Prognostic Factors Post-Allogeneic Stem Cell Transplant                                    Normal or not                                                                                     Prospective                   65                  70                                Advanced            CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     LDH                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     KPS                                                                 [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref047]\]           Response and Survival Post IFN-α then IL-2.                                                ≥8                                                                                                Retrospective                 55                  99                                Metastatic          Nuclear grade                                                       [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Mastectomy                                                          [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     LDH                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref052]\]           CRP, Thrombocytosis and Recurrence                                                         \>10                                                                                              Retrospective                 55                  178                               All stages          Metastasis                                                          [d](#t003fn007){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     CRP                                                                 [c](#t003fn006){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Tumor grade                                                         [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Tumor size                                                          [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref050]\]           Primary Operable Tumor Recurrence                                                          \>10mg/L                                                                                          Prospective                   75                  83                                All Stages          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     UISS                                                                [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     SSIGN                                                               [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref051]\]           CRP, Tumoral IL-6, COX-2 Expression & Recurrence Free Survival                             10mg/L                                                                                            Retrospective                 60                  60                                Resectable          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     TNM                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref032]\]           Worst Grade Component And Recurrence                                                       ≥10 mg/L                                                                                          Retrospective                 50                  314                               All Stages          CRP                                                                 [c](#t003fn006){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref053]\]           Preoperative CRP and Metastasis                                                            Continuous                                                                                        Prospective                   85                  130                               All Stages          Pre-operative CRP                                                   ---, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     SSIGN                                                               [d](#t003fn007){ref-type="table-fn"},---
  **2010** \[[@pone.0143080.ref048]\]           Pre-operative CRP and Disease Free Survival                                                15mg/L                                                                                            Retrospective                 60                  286                               All Stages          Log (CRP)                                                           [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Stage                                                               [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     MVI (invasion)                                                      [b](#t003fn005){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref049]\]           Postoperative CRP to Predict Recurrence                                                    Continuous                                                                                        Prospective                   70                  110                               Localized           Post-operative CRP                                                  [a](#t003fn004){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     T-stage                                                             [d](#t003fn007){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref054]\]           CRP and Recurrence                                                                         8mg/L                                                                                             Retrospective                 55                  177                               Resectable          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Tumor size                                                          [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref055]\]           Post-nephrectomy CRP, CRP Kinetics & Recurrence                                            10mg/L                                                                                            Retrospective                 55                  263                               Resectable          High Pre-operative CRP                                              -/[z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Non-normal CRP                                                      ---, z
                                                                                                                                                                                                                                                                                                                                                     MVI                                                                 ---/---
                                                                                                                                                                                                                                                                                                                                                     Tumor Necrosis                                                      ---/-
  **2011** \[[@pone.0143080.ref056]\]           Risk Factors for Metastasis                                                                4mg/L                                                                                             Retrospective                 50                  32                                Metastasis          CRP                                                                 [b](#t003fn005){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Symptoms                                                            [c](#t003fn006){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Size                                                                [b](#t003fn005){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Histologic Grade                                                    [a](#t003fn004){ref-type="table-fn"}, [y](#t003fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     Sarcoma Component                                                   [d](#t003fn007){ref-type="table-fn"}, [z](#t003fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                     MVI                                                                 [a](#t003fn004){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref156]\]           Post-operative CRP, Pre-operative Albumin and Recurrence                                   2mg/L                                                                                             Retrospective                 50                  40                                Resectable          Post-operative CRP                                                  [d](#t003fn007){ref-type="table-fn"}, [x](#t003fn008){ref-type="table-fn"}

\* All CRP levels reported in results correspond to serum levels unless otherwise specified.

^\#^ Since CRP values are reported in different units, for uniformity purposes we converted all values to mg/L unless otherwise specified.

^ϕ^ Strongest predictors by MVA were stratified by relative risk (RR) and statistical significances (p) as follows:

^a^ RR\<2 or \>0.5

^b^ RR\>2 or \<0.5

^c^ RR\>5 or \<0.2

^d^ RR\>10 or \<0.1

^x^ p\<0.05

^y^ p\<0.01

^z^ p\<0.001

---values not reported or no MVA

**Abbreviations**: **ALP**: Alkaline Phosphatase; **APP**: Acute Phase Protein(s); **DFI**: Disease Free Interval; **DSS**: Disease Specific Survival; Score; LDH: Lactate Dehydrogenase; **LN**: lymph Node(s); **MP**: Medroxyprogesterone; **MSKCC**: Memorial Sloan-Kettering Cancer Center; **MVI:** Micro vascular Invasion; **MVA**: Multivariate Analysis; **RFS**: Recurrence Free Survival; **RR**: Relative Risk; **SSIGN**: Stage Size Grade Necrosis; **UISS**: University of California Los Angeles Integrated Staging System; **WCC**: White Cell Count.

1.2. Treatment response: Thirteen of the 51 studies in renal cell carcinoma had treatment response and prognosis as a primary outcome \[[@pone.0143080.ref038], [@pone.0143080.ref040]--[@pone.0143080.ref051]\]. In 12 of the thirteen, CRP independently predicted both treatment response and prognosis. Six studies \[[@pone.0143080.ref040], [@pone.0143080.ref044], [@pone.0143080.ref048]--[@pone.0143080.ref051]\] investigated CRP and treatment response as a primary outcome. High CRP predicted treatment response in all except one \[[@pone.0143080.ref038]\]. This study was also underpowered, and the primary objective was not treatment response ([Table 3](#pone.0143080.t003){ref-type="table"}). Treatment responses (ill-defined) were evaluated after resection of localized tumors and after cytokine based therapies (IL-2 infusions, IF-α) in metastatic RCC. Low CRP level was associated with better treatment responses overall in 11 of thirteen studies.

1.3. Tumor recurrence: Six of the 51 renal cell carcinoma studies \[[@pone.0143080.ref032], [@pone.0143080.ref052]--[@pone.0143080.ref056]\] investigated recurrence and survival as primary outcomes. In three studies, elevated CRP independently predicted both tumor recurrence and prognosis \[[@pone.0143080.ref054], [@pone.0143080.ref056]\] ([Table 3](#pone.0143080.t003){ref-type="table"}). One of these \[[@pone.0143080.ref055]\] examined CRP kinetics (change in CRP over time) and identified non-normalization of postoperative CRP as a predictor of recurrence.

### 2. Gastrointestinal malignancies {#sec021}

Of 90 studies, 48 were in colorectal and 42 in esophageal, gastric or gastroesophageal cancers. In colorectal cancer, high CRP strongly predicted survival in 36 (75%) studies. High CRP was an independent prognostic indicator in most reports, 31 of 36 (65%). Only two \[[@pone.0143080.ref057], [@pone.0143080.ref058]\] were negative. In another ten studies \[[@pone.0143080.ref026], [@pone.0143080.ref059]--[@pone.0143080.ref066]\] CRP predicted prognosis by univariate analysis only; one of these was underpowered ([Table 2](#pone.0143080.t002){ref-type="table"}, [Fig 2](#pone.0143080.g002){ref-type="fig"}). Elevated CRP independently predicted prognosis in thirty five of the 42 (71%) studies in gastroesophageal cancer.

2.1. Prognosis: Most studies (81 of 90) in gastrointestinal malignancies had survival as a study outcome. Eighty percent (65 of 81) investigated CRP and prognosis as the primary outcome. High CRP was an independent predictor of survival in 56% (45 of 81) and a strong predictor in 25% (20 of 81). It was a predictor on univariate analysis only in 20% (16 0f 81). In two studies \[[@pone.0143080.ref026], [@pone.0143080.ref067]\], CRP predicted prognosis (but not independently of disease stage). Once this was considered, in those two, CRP was not a statistically significant prognostic predictor ([Table 4](#pone.0143080.t004){ref-type="table"}) \[[@pone.0143080.ref165]--[@pone.0143080.ref225]\].

10.1371/journal.pone.0143080.t004

###### CRP as a Predictor of Prognosis, Treatment Outcome or Tumor Recurrence in Digestive Tumors.

![](pone.0143080.t004){#pone.0143080.t004g}

  Publication Year (Reference)            Main Outcome                                                                             CRP cut-offs[\*](#t004fn002){ref-type="table-fn"} (mg/L)[^\#^](#t004fn003){ref-type="table-fn"}   Study Design                  Quality Score (%)   Sample Size            Disease Extent                        Strongest Predictors by MVA[^ϕ^](#t004fn004){ref-type="table-fn"}   
  --------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------- ------------------- ---------------------- ------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------
  **PROGNOSIS**                                                                                                                                                                                                                                                                                                                                                                                                         
  **Colorectal**                                                                                                                                                                                                                                                                                                                                                                                                        
  **1998** \[[@pone.0143080.ref165]\]     Preoperative CRP and Clinicopathologic Factors                                           \>8                                                                                               Prospective                   65                  120                    All stages                            CRP                                                                 ---
  **2000** \[[@pone.0143080.ref166]\]     PAI-1 and CRP Post-resection                                                             \>9.8                                                                                             Prospective                   70                  594                    All stages                            CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2003** \[[@pone.0143080.ref167]\]     Pre-/postoperative CRP in Curative Resection                                             \>10                                                                                              Prospective                   65                  174                    Dukes' A, B, C                        CSS CRP                                                             [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Dukes                                                               [c](#t004fn007){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2003** \[[@pone.0143080.ref168]\]     Deprivation, CRP in Curative Resection                                                   \>10                                                                                              Prospective                   65                  174                    Dukes' B, C                           CSS: Age                                                            [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Dukes'                                                              [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2004** \[[@pone.0143080.ref169]\]     Perioperative APP; IL-1,6 network                                                        ≥10                                                                                               Prospective                   60                  75                     All stages                            CRP                                                                 ---
  **2004** \[[@pone.0143080.ref170]\]     CRP in Potentially Curative Resection                                                    \>10                                                                                              Prospective                   65                  147                    Duke\'s B, C                          Dukes                                                               [c](#t004fn007){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2004** \[[@pone.0143080.ref171]\]     PH vs. Laparotomy Effects on Markers in Liver Metastasis                                 \>2                                                                                               Prospective                   70                  24 PH + 9 laparotomy   Liver metastasis                      DFS: CRP                                                            ---, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    HGF                                                                 ---, [x](#t004fn009){ref-type="table-fn"}
  **2005** \[[@pone.0143080.ref172]\]     IL-6, TNFα, CRP in Local Resection                                                       ≥7                                                                                                Prospective                   70                  74 + 25 controls       All stages                            Unclear: CRP                                                        ---
                                                                                                                                                                                                                                                                                                                                                    IL-6                                                                ---
  **2005** \[[@pone.0143080.ref173]\]     T-lymphocyte Infiltration + Preoperative CRP                                             \>10                                                                                              Prospective                   60                  147                    Dukes' B, C                           CSS: CRP                                                            [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Stage                                                               [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref174]\]     Nutritional and Inflammatory Status in Palliative Treatment                              \>10                                                                                              Prospective                   60                  51                     Advanced                              PS                                                                  [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    GPS                                                                 [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Treatment type                                                      [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref175]\]     CRP in patients receiving adjuvant 5-FU Post- curative Resection                         \>10                                                                                              Prospective                   60                  222                    Duke's A, B, C                        No adjuvant chemotherapy CRP                                        [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Adjuvant chemotherapy CRP                                           [c](#t004fn007){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref131]\]     GPS: Post Resection                                                                      \>10                                                                                              Prospective                   75                  316                    All stages                            mGPS                                                                [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref176]\]     Ki-67 Expression, CRP and Survival                                                       10mg/L                                                                                            Retrospective                 60                  147                    Curative                              CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Dukes                                                               [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref177]\]     mGPS and Prognosis                                                                       10mg/L                                                                                            Prospective                   70                  233                    All Stages                            mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Platelet                                                            [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Monocyte                                                            [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Neutrophil                                                          [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    WBC                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    TNM                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref178]\]     Pre-operative Score for Prognosis With Liver Metastasis                                  10mg/L                                                                                            Prospective with Control      75                  560                    Resectable                            IRT                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Metastasis Number                                                   [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2007** \[[@pone.0143080.ref179]\]     GPS and Post operative Mortality Prediction                                              10mg/L                                                                                            Retrospective                 65                  315                    All Stages                            GPS                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref180]\]     Preoperative and Perioperative CRP Levels and Prognosis                                  5mg/L                                                                                             Prospective                   80                  212                    All Stages                            CRP                                                                 [c](#t004fn007){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Differerentiation                                                   [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Stages                                                              [c](#t004fn007){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref181]\]     Preoperative CRP in CEA Independent Stage I or II CRC                                    5mg/L                                                                                             Retrospective                 60                  300                    All Stages                            CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref182]\]     Preoperative CRP and Prognosis                                                           5mg/L                                                                                             Retrospective                 65                  116                    All Stages                            CRP                                                                 [d](#t004fn008){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Stage                                                               [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Poor Differentiation                                                [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref183]\]     Pre-treatment Levels of IL-6, CRP                                                        9.7mg/L                                                                                           Retrospective with control    65                  76, C: 35              All Stages                            Tumor Residue                                                       ---/ [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CRP                                                                 ---/ [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CA 19--9                                                            ---/ [x](#t004fn009){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref184]\]     Systemic Inflammatory Response (SIR); GPS; Gene Polymorphism                             10mg/L (GPS)                                                                                      Prospective                   55                  56                     Advanced                              GPS: 1                                                              [d](#t004fn008){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Albumin                                                             [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Primary Site                                                        [c](#t004fn007){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref185]\]     Emergency (ER) Presentation, Preoperative mGPS and Survival                              10mg/L                                                                                            Prospective                   70                  188                    Curative                              mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Presentation, ER/Elective                                           [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref186]\]     Systemic Inflammatory Response (SIR) with Liver Metastasis                               10mg/L                                                                                            Retrospective                 65                  93                     Metastasis                            CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Number of Tumors                                                    [b](#t004fn006){ref-type="table-fn"}, x
                                                                                                                                                                                                                                                                                                                                                    Hepatectomy                                                         [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Lung metastasis                                                     [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref187]\]     Local (Klintrup and Jass score) v. Systemic Inflammatory Response (mGPS) and Prognosis   10mg/L (mGPS)                                                                                     Retrospective                 60                  287                    Curative                              mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Dukes                                                               [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Klintrup                                                            [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref188]\]     mGPS and Survival                                                                        10mg/L (mGPS)                                                                                     Retrospective                 60                  112                    Unresectable                          mGPS                                                                [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref189]\]     Survival Predictors in Stage IV metastasis                                               \<50, 50--150, \>150                                                                              Retrospective                 55                  541                    Advanced                              CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Chemotherapy                                                        [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    PS                                                                  [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Hb                                                                  [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Weight Loss                                                         [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Anorexia                                                            [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Fatigue                                                             [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Blood Transfusion                                                   [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref190]\]     Pre-resection GPS and Survival                                                           10mg/L (GPS)                                                                                      Prospective                   65                  63                     Metastasis                            GPS                                                                 [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Liver metastasis                                                    [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref191]\]     Obesity, Insulin Resistance, Inflammation, Angiogenesis and Survival                     4.1                                                                                               Prospective                   60                  344                    All Stages                            CRP                                                                 [a](#t004fn005){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    VEGF-A                                                              [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Ang-2                                                               [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref192]\]     Systemic inflammatory Response Before Curative Resection and Survival                    10mg/L (mGPS)                                                                                     Retrospective                 55                  320                    All Stages                            mGPS                                                                [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Smoking                                                             [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Dukes                                                               [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    POSSUM                                                              [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref193]\]     mGPS and Prognosis, Effect of Adjuvant Chemotherapy                                      5mg/L (mGPS)                                                                                      Retrospective                 55                  219                    Specific Stages, Stage II and III     mGPS                                                                [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Pathology                                                           [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref194]\]     Hsp70, Acute Phase Proteins (CRP, C1 Inhibitor, C3, C9) and Prognosis                    4.7mg/L                                                                                           Retrospective                 65                  175                    All Stages                            CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    sHsp70                                                              [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref195]\]     Pre-operative Comorbidity, Systemic Inflammation and Survival                            10mg/L (mGPS)                                                                                     Retrospective                 55                  302                    All Stages                            mGPS                                                                [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    TNM                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Peterson                                                            [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    ACE-27                                                              [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref063]\]     CRP & Prognosis: Peritoneal Carcinomatosis + CRC                                         35mg/L, Other Cutoffs                                                                             Retrospective                 50                  50                     Advanced                              CRP                                                                 ---/[z](#t004fn011){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref196]\]     Preoperative Thrombocytosis and Survival After Surgery                                   Continuous                                                                                        Retrospective                 55                  453                    All Stages                            CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CEA                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Tumor Number                                                        [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Platelet                                                            [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref197]\]     GPS in Synchronous and Metachronous Liver Metastasis                                     10mg/L (GPS)                                                                                      Retrospective                 50                  40                     All Stages                            GPS 2                                                               [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CA19-9                                                              [d](#t004fn008){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CEA                                                                 [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref198]\]     GPS and survival: Undergoing Curative Surgery                                            10mg/L (GPS)                                                                                      Retrospective                 55                  366                    Specific Stages, TNM Stage II & III   GPS                                                                 [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN Mets                                                             [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Lymphatic Invasion                                                  [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Invasion depth                                                      [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **Esophagus**                                                                                                                                                                                                                                                                                                                                                                                                         
  **2003** \[[@pone.0143080.ref199]\]     Clinical outcomes & Predictors Before Therapy                                            ≥ 5                                                                                               Retrospective                 60                  356                    All stages                            TNM                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Weight Change                                                       [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2003** \[[@pone.0143080.ref200]\]     Clinicopathological & the Prognostic Value of Pre-operative CRP                          10mg/L                                                                                            Retrospective                 60                  150                    All Stages                            CRP (low vs. high)                                                  [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN status                                                           [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2005** \[[@pone.0143080.ref201]\]     Pretreatment CRP in Chemo/radiation                                                      ≥6                                                                                                Prospective                   65                  67 + 20 controls       All stages                            CRP                                                                 ---, [y](#t004fn010){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref202]\]     Preoperative CRP in Adeno- and Squamous Cell Carcinoma Post-Resection                    ≥50                                                                                               Prospective                   60                  291                    All stages                            pT stage                                                            ---, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    R classification                                                    ---, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Transthoracic approach                                              [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2006** \[[@pone.0143080.ref203]\]     Clinico-pathological Status & Preop. CRP                                                 \>5 and \>10                                                                                      Prospective                   70                  120                    All stages                            CRP\>10                                                             [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN metastases                                                       [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref204]\]     GPS and Survival Prior nCRT                                                              10mg/L (GPS)                                                                                      Retrospective                 70                  48                     Specific Stages, Stage II and III     GPS                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2009** \[[@pone.0143080.ref205]\]     Biomarkers and Survival                                                                  \<5mg/L, ≥ 5mg/L                                                                                  Prospective                   65                  123                    All Stages                            CRP                                                                 [d](#t004fn008){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Treatment                                                           [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Albumin                                                             [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref027]\]     nCRT Followed by Surgery                                                                 8mg/L, 10mg/L                                                                                     Prospective with Control      70                  90, C: 105             Resectable                            CRP                                                                 [c](#t004fn007){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    UICC                                                                [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Radicality                                                          [c](#t004fn007){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref206]\]     GPS and Survival in Oesophageal Carcinoma (SCC)                                          10mg/L                                                                                            Prospective                   75                  65                     Locally Advanced                      GPS                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN Number                                                           [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Curability                                                          [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref207]\]     Locally Advanced Disease Undergoing Induction CRT                                        3mg/L                                                                                             Retrospective                 55                  34                     Advanced                              High CRP (After Chemotherapy)                                       -/ [x](#t004fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref208]\]     GPS in Homogenous Esophageal Cancer                                                      10mg/L (GPS)                                                                                      Retrospective                 65                  495                    esectable                             SCC: GPS1                                                           [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    GPS2                                                                [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Adeno: GPS1                                                         [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    GPS2                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref209]\]     Inflammatory Markers Surgical Resection & Prognosis                                      10mg/L mGPS                                                                                       Retrospective                 55                  112                    Resectable                            \+ LN Ratio                                                         [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref210]\]     Local/Systemic Inflammatory Response & Survival                                          10mg/L mGPS                                                                                       Prospective                   60                  121                    All Stages                            mGPS                                                                [d](#t004fn008){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    \+ LN ratio                                                         [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    CD68 (K-M Score)                                                    [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref129]\]     CRP and Albumin & Risk stratification                                                    5 mg/L (Fuzzy Score)                                                                              Retrospective                 55                  271                    All Stages                            Fuzzy                                                               [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    BMI                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Treatment                                                           [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    TNM Stage                                                           [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref024]\]     Serum CRP and Histological Subtype                                                       5.75 mg/L                                                                                         Prospective with control      70                  53 C:90                All Stages                            EC, CRP                                                             -/ [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    ESCC, CRP                                                           -/ [x](#t004fn009){ref-type="table-fn"}
  **Gastro-esophageal**                                                                                                                                                                                                                                                                                                                                                                                                 
  **2006** \[[@pone.0143080.ref211]\]     IL-1β, IL-6, IL-8, TNF-α mRNA, Protein: Tumoral & Systemic Levels                        \>10                                                                                              Prospective                   70                  56 + 22 controls       All stages                            CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  IL-1β infiltrate                        ---                                                                                                                                                                                                                                                                                                                                                                           
  **2006** \[[@pone.0143080.ref203]\]     GPS in Inoperable Cancer                                                                 \>10                                                                                              Prospective                   60                  258                    All stages                            Active treatment, GPS                                               [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Stage TNM                                                           [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Treatment                                                           [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Supportive treatment Stage                                          [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **1982** \[[@pone.0143080.ref212]\]     Postoperative Survival and Pretreatment CEA, Albumin, CRP, ACT, AGP                      \>10                                                                                              Prospective                   55                  104                    All stages                            ACT                                                                 ---
                                                                                                                                                                                                                                                                                                                                                    CRP                                                                 ---
                                                                                                                                                                                                                                                                                                                                                    AGP                                                                 ---
  **2007** \[[@pone.0143080.ref108]\]     Factors Predictive of Death. Risk Prediction Model                                       5mg/L                                                                                             Prospective                   70                  220                    All Stages                            CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    WL Rate                                                             [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Karnofsky                                                           [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Stage IV                                                            [c](#t004fn007){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2008** \[[@pone.0143080.ref127]\]     GPS & ECOG-PS: Survival & Treatment Response                                             10mg/L                                                                                            Prospective                   60                  65                     All Stages                            GPS                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref213]\]     Pre-treatment Clinical Prognostic Factors and Survival                                   10mg/L (GPS)                                                                                      Retrospective                 60                  217                    All Stages                            mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    TNM Stage                                                           [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Position                                                            [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref214]\]     Tumor proliferation, Systemic Inflammatory Response and Survival                         10mg/L mGPS                                                                                       Prospective                   60                  100                    All Stages                            mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN ratio                                                            [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Tumor Differentiation                                               [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Klintrup                                                            [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Ki-67                                                               [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **Gastric**                                                                                                                                                                                                                                                                                                                                                                                                           
  **1983** \[[@pone.0143080.ref215]\]     Preoperative CEA, CRP, GGT, PHI, Pseudouridine, ACT, AAG                                 \>20                                                                                              Prospective                   70                  200 + 73 C             All stages                            Gastric CRP                                                         ---
                                                                                                                                                                                                                                                                                                                                                    Colorectal Dukes                                                    ---
  **2010** \[[@pone.0143080.ref102]\]     Preoperative CRP and Survival                                                            3mg/L                                                                                             Prospective with controls     80                  170, C: 405            Resectable                            CRP                                                                 ---/ [y](#t004fn010){ref-type="table-fn"}
  **2010** \[[@pone.0143080.ref216]\]     Hypoalbuminemia, High CRP and Survival                                                   ≤10, \>10                                                                                         Retrospective                 60                  217                    All Stages                            Continuous CRP                                                      [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Categorical CRP                                                     [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Act. Pall.                                                          [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    TNM IV                                                              [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref217]\]     Preoperative CRP                                                                         5mg/L                                                                                             Retrospective                 60                  204                    Curative                              Preoperative CRP                                                    [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Tumor Stage                                                         [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN Invasion                                                         [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref218]\]     GPS and Prognosis                                                                        10mg/L TGPS, 5mg/L MGPS                                                                           Retrospective                 65                  232                    Resectable                            TGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Stage                                                               [d](#t004fn008){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    MGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref219]\]     Peritoneal Dissemination and Prognosis                                                   20mg/L                                                                                            Retrospective                 55                  79                     Metastasis                            CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Albumin                                                             [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Ascites                                                             [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    ECOG PS                                                             [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref097]\]     Clinical Status, Laboratory factors and Survival                                         10mg/L GPS                                                                                        Retrospective                 55                  402                    Metastasis                            GPS 1                                                               [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    GPS 2                                                               [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    ECOG PS                                                             [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref220]\]     CRP & Potential Prognostic Factors                                                       10mg/L                                                                                            Retrospective                 50                  61                     Metastasis                            CRP                                                                 [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Gender                                                              [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref221]\]     mGPS and Prognosis                                                                       10mg/L mGPS                                                                                       Retrospective                 55                  1710                   All Stages                            mGPS                                                                [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Tumor Stage                                                         [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref222]\]     GPS and Survival                                                                         10mg/L GPS                                                                                        Retrospective                 50                  83                     Advanced                              GPS                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref223]\]     NLR and mGPS in Advanced Stage                                                           10mg/LmGPS                                                                                        Retrospective                 55                  104                    Unresectable                          mGPS1                                                               [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    mGPS2                                                               [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    NLR                                                                 [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN Mets                                                             [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref228]\]     GPS before curative surgery and survival                                                 10mg/L GPS                                                                                        Retrospective                 55                  366                    Specific stages: TNM Stage II & III   GPS                                                                 [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN Metastasis                                                       [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN Invasion                                                         [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Invasion Depth                                                      [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref128]\]     Markers of Systemic Inflammatory Response and Prognosis                                  10mg/L mGPS                                                                                       Prospective                   60                  120                    All Stages                            mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    LN Ratio                                                            [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **Gastric + Colorectal**                                                                                                                                                                                                                                                                                                                                                                                              
  **2000** \[[@pone.0143080.ref224]\]     Metastasis, KPS Anthropometry, Appetite, Blood Markers, and CRP                          \>10                                                                                              Prospective                   70                  91                     Locally Advanced or Metastatic        CRP                                                                 ---, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    KPS                                                                 ---, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Mets                                                                ---, [x](#t004fn009){ref-type="table-fn"}
  **Other Gastrointestinal**                                                                                                                                                                                                                                                                                                                                                                                            
  **2004** \[[@pone.0143080.ref225]\]     Albumin, CRP                                                                             \>10                                                                                              Retrospective                 60                  165                    Advanced                              GPS                                                                 ---, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Tumor type                                                          ---, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Age                                                                 ---, [x](#t004fn009){ref-type="table-fn"}
  **Tumor Recurrence**                                                                                                                                                                                                                                                                                                                                                                                                  
  **Colorectal**                                                                                                                                                                                                                                                                                                                                                                                                        
  **1995** \[[@pone.0143080.ref226]\]     APR (CRP)                                                                                \>5                                                                                               Prospective                   70                  36                     Duke's B/C                            CRP                                                                 ---
  **2001** \[[@pone.0143080.ref227]\]     CEA, CA19-9 and CRP                                                                      \>0.5 ng/ml                                                                                       Prospective                   60                  82                     Dukes' A, B,C                         CRP                                                                 ---
                                                                                                                                                                                                                                                                                                                                                    CA 19--9                                                            ---
  **2007** \[[@pone.0143080.ref178]\]     Pre-operative Inflammatory Response Scoring System & Recurrence                          10mg/L                                                                                            Prospective with Control      75                  560                    Resectable                            IRT                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Number of metastasis                                                [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **Esophagus**                                                                                                                                                                                                                                                                                                                                                                                                         
  **2003** \[[@pone.0143080.ref228]\]     Outcomes Post-Recurrence                                                                 ≥10                                                                                               Prospective + Retrospective   55                  258                    All stages                            S-p53-Abs                                                           [d](#t004fn008){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  CRP                                     [c](#t004fn007){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                    
  **2011** \[[@pone.0143080.ref208]\]     GPS and Recurrence in Homogenous Esophageal Cancer                                       10mg/L GPS                                                                                        Retrospective                 65                  495                    Resectable                            SCC: GPS1                                                           [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    GPS2                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Adeno: GPS1                                                         [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    GPS2                                                                [b](#t004fn006){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
  **Gastric**                                                                                                                                                                                                                                                                                                                                                                                                           
  **2011** \[[@pone.0143080.ref097]\]     Laboratory Factors and Progression                                                       10mg/L GPS                                                                                        Retrospective                 55                  402                    Metastasis                            CRP                                                                 [a](#t004fn005){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    ECOG PS                                                             [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Bone Metastasis                                                     [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref220]\]     CRP and Gastric Cancer Progression                                                       10mg/L                                                                                            Retrospective                 50                  61                     Metastasis                            CRP                                                                 ---/ [z](#t004fn011){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref229]\]     Inflammation Based Prognostic Score and Recurrence                                       5mg/L                                                                                             Retrospective                 60                  197                    Locally Advanced                      Inflammatory Score                                                  [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    TNM                                                                 [d](#t004fn008){ref-type="table-fn"}, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Serous Invasion                                                     [a](#t004fn005){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2012** \[[@pone.0143080.ref222]\]     GPS and Recurrence                                                                       10mg/L GPS                                                                                        Retrospective                 50                  83                     Advanced                              GPS                                                                 [a](#t004fn005){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
  **Gastric + Colorectal**                                                                                                                                                                                                                                                                                                                                                                                              
  **2000** \[[@pone.0143080.ref224]\]     CRP, Metastasis, KPS and Blood Markers                                                   \>10                                                                                              Prospective                   70                  91                     Locally Advanced or Metastatic        CRP                                                                 ---, [z](#t004fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    KPS                                                                 ---, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Mets                                                                ---, [x](#t004fn009){ref-type="table-fn"}
  **Treatment Response and/or Staging**                                                                                                                                                                                                                                                                                                                                                                                 
  **Colorectal**                                                                                                                                                                                                                                                                                                                                                                                                        
  **1995** \[[@pone.0143080.ref230]\]     Pre-treatment APP (4); Response to Immuno- chemotherapy                                  \>10                                                                                              Prospective                   55                  24                     Metastatic                            CRP                                                                 ---
                                                                                                                                                                                                                                                                                                                                                    Albumin                                                             ---
                                                                                                                                                                                                                                                                                                                                                    α1-AT                                                               ---
  **2006** \[[@pone.0143080.ref175]\]     Adjuvant 5-FU Post Resection + Survival                                                  \>10                                                                                              Prospective                   60                  222                    Dukes A, B, C                         CRP                                                                 [c](#t004fn007){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **2011** \[[@pone.0143080.ref193]\]     mGPS and Response in Potentially Curative Resection                                      5 mg/L (mGPS)                                                                                     Retrospective                 55                  219                    Specific Stage: Stage II              mGPS                                                                [b](#t004fn006){ref-type="table-fn"}, [y](#t004fn010){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                    Pathology                                                           [b](#t004fn006){ref-type="table-fn"}, [x](#t004fn009){ref-type="table-fn"}
  **Esophagus**                                                                                                                                                                                                                                                                                                                                                                                                         
  **2005** \[[@pone.0143080.ref201]\]     Pretreatment CRP in CRT + Survival                                                       ≥6                                                                                                Prospective                   65                  67 + 20 controls       All stages                            CRP                                                                 ---
  **2011** \[[@pone.0143080.ref207]\]     Locally Advanced Disease Under Induction CRT                                             3mg/L                                                                                             Retrospective                 55                  34                     Advanced                              CRP (Post CRT)                                                      -/[y](#t004fn010){ref-type="table-fn"}
  **Gastro-esophageal**                                                                                                                                                                                                                                                                                                                                                                                                 
  **2008** \[[@pone.0143080.ref127]\]     GPS, ECOG-PS & Clinical Response                                                         10mg/L                                                                                            Prospective                   60                  65                     All Stages                            GPS                                                                 ---/[x](#t004fn009){ref-type="table-fn"}

Notes: (86, 89) are survival studies where treatment response was also an outcome.

\* All CRP levels reported in results correspond to serum levels unless otherwise specified.

^\#^ Since CRP values are reported in different units, for uniformity purposes we converted all values to mg/L unless otherwise specified.

^ϕ^ Strongest predictors by MVA were stratified by relative risk (RR) and statistical significances (p) as follows:

^a^ RR\<2 or \>0.5

^b^ RR\>2 or \<0.5

^c^ RR\>5 or \<0.2

^d^ RR\>10 or \<0.1

^x^ p\<0.05

^y^ p\<0.01

^z^ p\<0.001

---Values not reported or no MVA

**Abbreviations**: **AAG**: α1 acid glycoprotein; **α1-AT**: α1 Antitryspsin; **ACE-27**: Adult Comorbidity Evaluation-27: **ACT**: α1 Antichymotryspsin; **ALP**: Alkaline Phosphatase; **APP**: Acute Phase Protein(s); **CEA**: Carcinoembryonic Antigen; **CRT**: Chemoradiotherapy; **FU**: Fluorouracil: **GGT**: Gamma Glutamyl Transferase; **GPS**: Glagcow Prognostic Score; **HGF**: Hepatocyte Growth Factor; **HsP**: Heat Shock Protein; **IAP**: Immunosuppressive Acid Protein; **IL**: Interleukin; **LN**: Lymph Node; **MVA**: Multivariate Analysis; **PAI**: Plasminogen Activator Inhibitor-1; **PH**: Partial Hepatectomy; **PHI**: Phosphohexose Isomerase; **PS**: Performance Status; **RR**: Relative Risk; **SCC**: Squamous Cell Carcinoma; **TNF**: Tumor Necrosis Factor; **↑**: Increase; **↓**: Decrease.

2.2. Treatment response or tumor stage: CRP predicted treatment response in six studies \[[@pone.0143080.ref127], [@pone.0143080.ref175], [@pone.0143080.ref193], [@pone.0143080.ref201], [@pone.0143080.ref207], [@pone.0143080.ref230]\] ([Table 4](#pone.0143080.t004){ref-type="table"}). It did not predict stage in one study \[[@pone.0143080.ref057]\] but this was underpowered ([Table 4](#pone.0143080.t004){ref-type="table"}). Treatment responses were evaluated after curative resection followed by adjuvant 5-Flurouracil (5-FU) in localized GI tumors. Responses after neo-adjuvant chemotherapy, chemo-radiotherapy, and IL-2 infusions (with either 5FU or surgery) were observed in advanced tumors. In 4 of the five studies, high CRP level was associated with poorer responses.

2.3. Tumor recurrence: Ten of the 90 GI studies investigated recurrence as a primary outcome. In six of the ten, high CRP independently predicted recurrence. One study did not \[[@pone.0143080.ref059]\]; it included both retrospective and prospective cohorts. Furthermore, CRP prediction of recurrence was not the main outcome \[[@pone.0143080.ref226]--[@pone.0143080.ref230]\] ([Table 4](#pone.0143080.t004){ref-type="table"}). High CRP was a strong predictor of recurrence in the rest of the other studies.

### 3. Other Solid Tumors {#sec022}

24 studies (each) investigated CRP and prognosis in pancreatic and lung cancer. CRP predicted prognosis in 23 of 24 (96%) studies in pancreatic cancer \[[@pone.0143080.ref068]--[@pone.0143080.ref071]\], 22 of 24 (92%) in lung cancer \[[@pone.0143080.ref025], [@pone.0143080.ref072]--[@pone.0143080.ref074]\], all 10 in hepatocellular carcinoma (HCC) \[[@pone.0143080.ref075]--[@pone.0143080.ref077]\], all 5 in melanoma \[[@pone.0143080.ref023], [@pone.0143080.ref078]\], 4 of 7 (57%) in breast cancer \[[@pone.0143080.ref079], [@pone.0143080.ref080]\], 12 of 12 (100%) in bladder cancer \[[@pone.0143080.ref081]--[@pone.0143080.ref083]\], 7 of 9 (78%) in prostate cancer \[[@pone.0143080.ref084]--[@pone.0143080.ref086]\] and 21 of 24 (88%) others (cervical cancer, ovarian cancer, bone and soft tissue etc.) \[[@pone.0143080.ref087]--[@pone.0143080.ref091]\]. 14 of 15 (93%) studies of heterogeneous cancers found high CRP to be a predictor of prognosis \[[@pone.0143080.ref092]--[@pone.0143080.ref094]\] ([Table 2](#pone.0143080.t002){ref-type="table"}, [Fig 2](#pone.0143080.g002){ref-type="fig"}).

CRP and prognosis by univariate analysis {#sec023}
----------------------------------------

CRP as a prognostic indicator was investigated as the primary outcome in most of these studies. Eighteen percent of all studies (48 of 271) found CRP prognostic only by univariate analysis. The forty eight consisted of 12 in renal cell carcinoma; 10 in colorectal cancer; 6 in gastroesophageal; 7 in pancreas; 2 each in lung and bladder; 2 in heterogeneous groups; 1 in hepatocellular cancer and 6 in others (ovarian, primary bone and soft tissue cancers, oral squamous cell carcinoma, hepatocellular carcinoma and malignant histiocytoma) \[[@pone.0143080.ref231]--[@pone.0143080.ref246]\] ([S3 Appendix](#pone.0143080.s003){ref-type="supplementary-material"}). The median sample size was one hundred fifty five (range 38--9608). Thirty included various disease stages, and another 18 advanced, or metastatic/recurrent disease \[[@pone.0143080.ref059], [@pone.0143080.ref063], [@pone.0143080.ref066], [@pone.0143080.ref095]--[@pone.0143080.ref101]\]. One had an adequate quality score \[[@pone.0143080.ref102]\], forty three intermediate. 4 were underpowered \[[@pone.0143080.ref039], [@pone.0143080.ref059], [@pone.0143080.ref095], [@pone.0143080.ref103]\].

Negative studies {#sec024}
----------------

Overall, CRP was not prognostic in 26 of 271 studies (17 prospective, 9 retrospective) ([S4 Appendix](#pone.0143080.s004){ref-type="supplementary-material"}). These included 9 in digestive tumors; 5 in renal cell carcinoma; 3 in breast; 2 each in lung and prostate; 1 in pancreas; 1 in heterogeneous and 3 in other cancers patients. Median sample size was one hundred thirty eight (range 31--329). 15 of the 26 included various disease stages \[[@pone.0143080.ref057], [@pone.0143080.ref058], [@pone.0143080.ref065], [@pone.0143080.ref080], [@pone.0143080.ref104]--[@pone.0143080.ref110]\]. The others were resectable/unresectable or advanced/locally advanced and/or metastatic disease \[[@pone.0143080.ref038], [@pone.0143080.ref111]--[@pone.0143080.ref113]\]. Although all had intermediate quality scores, three were also underpowered \[[@pone.0143080.ref038], [@pone.0143080.ref057], [@pone.0143080.ref112]\]. In most negative studies, CRP as a prognostic indicator was not the primary outcome measure \[[@pone.0143080.ref247]--[@pone.0143080.ref255]\] ([S4 Appendix](#pone.0143080.s004){ref-type="supplementary-material"}).

Additional parameters used for prognosis {#sec025}
----------------------------------------

CRP was used alone in 6% (15 of 271). Many studies considered more than one parameter for prognostic purpose. Demographic characteristics (age, gender, sex) were included as prognostic parameters in 66% of studies (170/256). Common clinicopathologic parameters included with CRP were: stage (TNM, Dukes, others) 23% (59/256); metastasis (lymph node, liver, others) 17%; performance status (ECOG, KPS, others) 16%; tumor characteristics (histology, site, diameter, size) 16%; WBC 13%. Biochemical parameters used with CRP (specifically in renal cell carcinoma) were: albumin (alone or as hypoalbuminemia), LDH, and interleukins (IL-6, IL-8, IL-2). In digestive tumors common biochemical parameters used were: albumin (alone or hypoalbuminemia), carcinoembryonic antigen (CEA), cancer antigen 19--9 (CA19-9) and interleukins (IL-6, IL-8, IL-2).

Discussion {#sec026}
==========

Summary of evidence {#sec027}
-------------------

Efforts to improve prognostication in cancer had limited success \[[@pone.0143080.ref114]\]. The number of cancer prognostic biomarkers validated as clinically useful is small, despite extensive research \[[@pone.0143080.ref115], [@pone.0143080.ref116]\]. Many studies have been underpowered. These studies are also difficult to interpret and compare because of heterogeneous study designs. This has prevented meta-analyses of prognostic biologic markers \[[@pone.0143080.ref004], [@pone.0143080.ref117]\]. We encountered this same difficulty during this systematic review.

Although thirty four percent of the studies (92 of 271) used an elevated CRP cut-off point of \>10mg/L, the rest varied. The cut-off value was not reported at all in twenty one studies, and simply as present/absent, or positive/negative in others. Reported cut-off values extended over a wide range: 0.5ng/ml, 1ng/ml, \>94nmol/L, \>2mg/L, \>5mg/L, \>8mg/L, \> 11 or 12 mg/L, \> 35 or 50 mg/L. This made meaningful study comparisons difficult. We tried to standardize if not, cut-off values, then at least the units used. All the studies (except one of the high sensitivity CRP) used CRP. Most (\>90%) of CRP levels were reported either in milligram per liter or milligram per deciliter (mg/L or mg/dL).

High sensitivity CRP (hs-CRP), tumoral CRP and CRP kinetics have also been utilized for disease progression and prognosis. Increased hs-CRP has been associated with late recurrence in renal cell carcinoma \[[@pone.0143080.ref119]\] and with increased mortality in breast cancer \[[@pone.0143080.ref079]\] and in men with lung cancer \[[@pone.0143080.ref118]\]. Tumoral CRP (increased locally within the tumor) may be superior to serum CRP for prognosis and recurrence \[[@pone.0143080.ref120]\]. Determined by CRP gene expression, tumoral CRP values are more personalized and rather a target for individualized therapy \[[@pone.0143080.ref121]\]. CRP kinetics may predict survival \[[@pone.0143080.ref122]\], recurrence \[[@pone.0143080.ref055]\] and clinical course \[[@pone.0143080.ref123]\] in cancer. Human CRP gene is located on the chromosome 1q21-23, spans 1.9 kb and has two exons. CRP gene polymorphism has been associated with increased cancer risk and worse prognosis, mainly in colorectal cancer \[[@pone.0143080.ref124], [@pone.0143080.ref125]\].

Various prognostic scoring systems and instruments have been developed utilizing CRP along with other clinical parameters. Prognostic Inflammatory Nutritional Index, PINI (CRP, Alpha-1 Acid Glycoprotein, albumin and prealbumin) \[[@pone.0143080.ref126]\]; Glasgow Prognostic Scale or Modified Glasgow Prognostic Scale (CRP, albumin); \[[@pone.0143080.ref050], [@pone.0143080.ref127], [@pone.0143080.ref128]\] Fuzzy Logic Based Prognostic Score (CRP and albumin) \[[@pone.0143080.ref129]\]; Biomarker Based Score (CRP, albumin, Gamma- Glutamyl Transferase (GGT) and HDL) \[[@pone.0143080.ref130]\]. GPS/mGPS and Fuzzy score only differ by CRP cutoffs. We included studies which utilized the Glasgow Prognostic Score or modified Glasgow Prognostic Score, as identified by the search criteria. We have not included studies which utilized Fuzzy score except for discussion purpose. The dominant biochemical component in both GPS and mGPS is CRP \[[@pone.0143080.ref131], [@pone.0143080.ref132]\]. One study defined mGPS as an Inflammation Based Index (IBI) and utilized it as a validated prognostic index for HCC \[[@pone.0143080.ref076]\].

CRP is a non-specific marker of inflammation. It can be elevated for many reasons: infection, invasive procedures, or medications \[[@pone.0143080.ref133], [@pone.0143080.ref134]\]. Inadequate screening for known non-cancer CRP-modifying factors may have significantly influenced values. In addition, it is accepted that sensitivity, specificity, positive and negative predictive values should be used to validate and compare any test against a gold standard \[[@pone.0143080.ref135]\]. Only two studies reported this data.

Inflammatory cells are tumor promoters. They produce an attractive environment for tumor growth, induce DNA damage, promote angiogenesis, and favor neoplastic spread and metastasis \[[@pone.0143080.ref092]\], and so may affect prognosis \[[@pone.0143080.ref017]\]. Several explanations exist for the proposed relationship between inflammation and the natural history of cancer. First, tumor growth itself can cause inflammation of surrounding tissue and increase plasma CRP \[[@pone.0143080.ref136]\]. Second, tumor cells produce various cytokines and chemokines that attract leukocytes. Some cancer cells express CRP and secrete interleukin-6 and interleukin-8, which stimulate liver CRP production \[[@pone.0143080.ref014], [@pone.0143080.ref136]\]. Studies have also shown that IL-6 blocks p-53 induced apoptosis. CRP-positivity develops a favorable microenvironment for the tumor cells through acute inflammatory cytokine network system maintenance \[[@pone.0143080.ref073]\]. Finally, CRP may be part of the host tumor immune response \[[@pone.0143080.ref136]\]. Evidence also suggests a causal role for chronic inflammation in several malignancies \[[@pone.0143080.ref014], [@pone.0143080.ref136], [@pone.0143080.ref137]\].

Cytokines and their surrogate markers (like CRP and IL-6 receptor) can be elevated both locally and systemically in different solid tumors. In renal cell carcinoma, the imbalance between pro-inflammatory cytokines and their anti-inflammatory counterpart is the therapeutic rationale behind immunotherapy \[[@pone.0143080.ref051], [@pone.0143080.ref138]\]. Colorectal cancer seems linked to chronic inflammation (both local and systemic) from genesis to progression \[[@pone.0143080.ref139]\]. Similar observations have been made in pancreatic \[[@pone.0143080.ref016]\] and lung cancers \[[@pone.0143080.ref140]\]. Those tumors are also highly associated with the cancer anorexia-cachexia syndrome, which itself may in part be due to inflammation \[[@pone.0143080.ref141]\].

The role of CRP as a prognostic marker for cardiovascular risk is widely known. Although studies have included large sample sizes, some skepticism still exists \[[@pone.0143080.ref012], [@pone.0143080.ref133]\]. It is noteworthy that a recently published study of 270,000 hospital patients, showed that high CRP levels not only predicted all-cause mortality (compared to the low/or normal CRP group), but also higher cancer mortality \[[@pone.0143080.ref142]\]. This study was retrospective and may have suffered from selection bias; those who had CRP measured were sicker and so had a higher risk of death.

In our review, most studies (over half) which met inclusion and quality criteria were in gastrointestinal and renal cell carcinoma. We were surprised not to see more investigations in lung and pancreatic cancer, since they are often considered clinically to have an inflammatory component. This was perhaps influenced by publication bias and selective reporting, i.e. positive studies published while some negative studies may not even be submitted for publication \[[@pone.0143080.ref143]\].

In our review, CRP appeared to be a valuable prognostic predictor particularly in digestive tumors and renal cell carcinoma. It may also help predict tumor recurrence and treatment response in those diseases. CRP was compared to other clinical and biochemical factors in these tumors. In renal cell carcinoma, grade, TNM staging, albumin and lactate dehydrogenase (LDH), were among the strongest prognostic predictors by multivariate analysis. Age, Dukes' stage, albumin, carcinoembryonic antigen (CEA) and the Glasgow Prognostic Score were amongst those in gastrointestinal tumors.

Does CRP add any extra information to these other predictors? CRP can be easily and reliably measured. However, it is a non-specific marker. Levels can rise for numerous reasons independent of the cancer; this also reduces the value of single versus serial CRP measurements. Longitudinal studies of CRP values were largely absent. Since CRP cut-off points differed among studies, and the sensitivity and specificity comparisons with different prognostic variables were unreported, it was impossible to conclude with certainty whether CRP was a better predictor than others. In the negative studies, the role of CRP as a prognostic predictor was not the primary outcome and most were underpowered to detect a difference.

Limitations {#sec028}
-----------

This review had several limitations. Survival and treatment outcomes in the literature were defined and reported inconsistently. Identification of studies depended on CRP being indexed, so we may have been more likely to identify positive studies. Quality assessment was conducted with no cross-validation. The QA system had been piloted on 10 studies picked randomly before the review. This showed it could distinguish between studies in the three QA categories (see Appendices). No meta-analysis or direct study comparisons were done because of the methodological issues described. For similar reasons side by side study comparisons were not possible.

Conclusions {#sec029}
===========

Increased CRP level predicted prognosis in most (90%) of the studies in solid tumors which met inclusion and quality criteria identified in this systematic review. More than half of all studies (52%) were in gastrointestinal malignancies or renal cell carcinoma. High CRP predicted prognosis in most reports (90%) in these two tumor groups. In addition CRP predicted prognosis in most reports in other solid tumors, so it may also be a clinically useful predictor in lung, pancreas, hepatocellular, and bladder cancers. CRP appeared to be a valuable (and probably under-recognized) prognostic predictor in these tumors. It may also have a role in determining treatment response, and tumor recurrence. The balance of evidence supports wider (and perhaps routine) use of CRP by oncologists for staging, assessment of tumor response and prognostication in at least these two tumor types. These conclusions and recommendations must be tempered by the intermediate quality of most studies.

Despite some methodological issues, CRP appears valuable to help predict prognosis and other important clinical outcomes in many solid tumors. Better quality prospective longitudinal studies on the role of CRP as a prognostic indicator are needed to confirm these observations.
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